1. Home
  2. ASND

as 05-20-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Founded: 2006 Country:
Denmark
Denmark
Employees: N/A City: N/A
Market Cap: 7.1B IPO Year: 2015
Target Price: $173.88 AVG Volume (30 days): 350.1K
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -9.64 EPS Growth: N/A
52 Week Low/High: $83.75 - $161.00 Next Earning Date: 05-02-2024
Revenue: $357,633,696 Revenue Growth: 322.18%
Revenue Growth (this year): 65.24% Revenue Growth (next year): 70.74%

Share on Social Networks: